PUBLIC COMPANY
save$ABBVAbbVie Inc.
$ABBV264.73-0.39%North Chicago, IL, USupdated 18h ago
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval168 co-mentions · 84 sources
- drugHUMIRA122 co-mentions · 61 sources
- drugadalimumab122 co-mentions · 61 sources
- drugABRILADA61 co-mentions · 61 sources
- drugYUSIMRY61 co-mentions · 61 sources
- drugAMJEVITA61 co-mentions · 61 sources
- drugSKYRIZI46 co-mentions · 23 sources
- drugrisankizumab46 co-mentions · 23 sources
pipeline
59
marketed
33
phase 3
3
catalysts ytd
30
approvals ytd
21
recalls ytd
0
Pipeline(59)
view full pipeline →pipeline depth59 products
2Phase 13Phase 23Phase 333Marketed16Unknown2pre_registration
Marketed
(avibactam sodium + aztreonam)
Complicated Intra-Abdominal Infections
Marketed(avibactam sodium + ceftazidime)
Pyelonephritis
Marketed(donepezil hydrochloride + memantine hydrochloride ER)
Dementia Associated With Alzheimer's Disease
Marketed(foscarbidopa + foslevodopa)
Parkinson's Disease
Marketed(glecaprevir + pibrentasvir)
Hepatitis C
MarketedCARIPRAZINE HYDROCHLORIDE
Autism Spectrum Disorder (ASD)
D(2) dopamine receptorD(3) dopamine receptor
MarketedCreon
Exocrine Pancreatic Insufficiency
MarketedLexapro
Generalized Anxiety Disorder (GAD)
MarketedLumigan
Ocular Hypertension
MarketedORIAHNN (COPACKAGED)
MarketedRestasis
Keratoconjunctivitis Sicca (Dry Eye)
Marketedadalimumab
Intermediate Uveitis
Upcoming
Recent(90d)
earnings (2)
🐶 Hiring Signal
next earnings Oct 29, 2026
Where AbbVie Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 5d ago
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 19d ago
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialAbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multip…fiercebiotech · 1mo ago
- Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateCurrent leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…biospace · 1mo ago
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…fiercebiotech · 1mo ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 2mo ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleSafety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…biospace · 2mo ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that